[go: up one dir, main page]

MX2009012666A - Composicion para el tratamiento de enfermedades isquemicas de las extremidades que se componen de celulas madre derivadas de tejido adiposo. - Google Patents

Composicion para el tratamiento de enfermedades isquemicas de las extremidades que se componen de celulas madre derivadas de tejido adiposo.

Info

Publication number
MX2009012666A
MX2009012666A MX2009012666A MX2009012666A MX2009012666A MX 2009012666 A MX2009012666 A MX 2009012666A MX 2009012666 A MX2009012666 A MX 2009012666A MX 2009012666 A MX2009012666 A MX 2009012666A MX 2009012666 A MX2009012666 A MX 2009012666A
Authority
MX
Mexico
Prior art keywords
composition
stem cells
adipose tissue
treating ischemic
ischemic limb
Prior art date
Application number
MX2009012666A
Other languages
English (en)
Inventor
Hae Jung Han
Hang Young Lee
Hyo Eun Kim
Original Assignee
Rnl Bio Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rnl Bio Co Ltd filed Critical Rnl Bio Co Ltd
Publication of MX2009012666A publication Critical patent/MX2009012666A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se divulgó en este documento una composición terapéutica celular para el tratamiento de enfermedades isquémicas en las extremidades inferiores, más específicamente, se divulgó una composición terapéutica celular para el tratamiento de enfermedades isquémicas que contienen células madre mesenquimatosas derivadas de tejido adiposo y sacarosa o manosa como un excipiente. La composición induce la angiogénesis alrededor de los vasos sanguíneos en las lesiones isquémicas de las extremidades inferiores, y de este modo es útil para tratar enfermedades isquémicas.
MX2009012666A 2007-05-25 2008-05-09 Composicion para el tratamiento de enfermedades isquemicas de las extremidades que se componen de celulas madre derivadas de tejido adiposo. MX2009012666A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020070050624A KR20080103637A (ko) 2007-05-25 2007-05-25 지방유래 줄기세포를 함유하는 사지말단부 허혈성 질환의세포치료용 조성물
PCT/KR2008/002614 WO2008147057A1 (en) 2007-05-25 2008-05-09 Composition for treating ischemic limb disease comprising stem cells derived from adipose tissue

Publications (1)

Publication Number Publication Date
MX2009012666A true MX2009012666A (es) 2010-02-18

Family

ID=40075249

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009012666A MX2009012666A (es) 2007-05-25 2008-05-09 Composicion para el tratamiento de enfermedades isquemicas de las extremidades que se componen de celulas madre derivadas de tejido adiposo.

Country Status (8)

Country Link
US (1) US20100196329A1 (es)
EP (1) EP2162141B1 (es)
JP (1) JP5290281B2 (es)
KR (1) KR20080103637A (es)
CN (1) CN101711160B (es)
ES (1) ES2431816T3 (es)
MX (1) MX2009012666A (es)
WO (1) WO2008147057A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2247285E (pt) 2007-11-30 2014-07-25 Rnl Bio Co Ltd Agente terapêutico celular para incontinência de urina compreendendo células estaminais originárias de decídua
TWI492707B (zh) * 2009-05-20 2015-07-21 卡迪歐參生物科技有限公司 治療心臟疾病之藥品配方
GB201202319D0 (en) 2012-02-10 2012-03-28 Orbsen Therapeutics Ltd Stromal stem cells
CN102920735A (zh) * 2012-11-14 2013-02-13 青岛奥克生物开发有限公司 一种间充质干细胞注射液及其制备方法和在制备治疗糖尿病药物中的应用
WO2014112607A1 (ja) * 2013-01-21 2014-07-24 国立大学法人名古屋大学 細胞製剤及び細胞の活性を高める方法
KR101583569B1 (ko) * 2013-05-15 2016-01-08 라정찬 정맥 투여용 줄기세포 조성물
JP2016008198A (ja) * 2014-06-24 2016-01-18 国立大学法人名古屋大学 間質性膀胱炎の治療
EP3178318B1 (en) * 2014-07-08 2020-08-26 Jeong Chan Ra Composition for promoting storage stability of stem cells
KR101613478B1 (ko) * 2014-09-22 2016-04-19 (주)안트로젠 중간엽줄기세포-하이드로겔을 함유하는 조성물 및 이의 제조방법
US10124038B2 (en) 2015-03-20 2018-11-13 Orbsen Therapeutics Limited Modulators of syndecan-2 and uses thereof
US11918687B2 (en) 2016-01-15 2024-03-05 Orbsen Therapeutics Limited SDC-2 exosome compositions and methods of isolation and use
MY176088A (en) * 2016-07-26 2020-07-24 Cytopeutics Sdn Bhd A cell-based composition and use thereof for treatment of psoriasis and systemic lupus erythematosus
KR101980562B1 (ko) * 2017-01-16 2019-05-21 사회복지법인 삼성생명공익재단 옥살산염을 이용한 줄기세포능 향상 방법
GB2560933A (en) * 2017-03-28 2018-10-03 Glaxosmithkline Ip Dev Ltd Transduced cell formulation
JP6256786B1 (ja) * 2017-04-12 2018-01-10 学校法人福岡大学 不妊症の処置に用いられる医薬組成物およびその製造方法
KR102722188B1 (ko) 2017-07-14 2024-10-24 오르브센 테라퓨틱스 리미티드 씨디39 기질 줄기세포 단리 방법 및 용도
WO2019044990A1 (ja) 2017-08-30 2019-03-07 富士フイルム株式会社 細胞移植用デバイスおよびその製造方法
EP3677289A4 (en) 2017-08-30 2020-08-26 FUJIFILM Corporation ANGIOGENIC AGENT AND PROCESS FOR THE PRODUCTION OF THE LATTER
CN112546070A (zh) * 2020-07-01 2021-03-26 陕西佰傲干细胞再生医学有限公司 间充质干细胞制剂及其制备方法和应用
JP7018527B1 (ja) 2020-12-16 2022-02-10 アニコム先進医療研究所株式会社 細胞の保存方法および細胞懸濁液
WO2023182609A1 (ko) * 2022-03-22 2023-09-28 가톨릭관동대학교산학협력단 지방 조직 유래 중간엽 줄기세포 및 인간 기질 혈관 분획을 포함하는 혈관신생 촉진용 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5045446A (en) * 1988-08-26 1991-09-03 Cryopharm Corporation Lyophilization of cells
US6972125B2 (en) * 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
US6777231B1 (en) 1999-03-10 2004-08-17 The Regents Of The University Of California Adipose-derived stem cells and lattices
US6436704B1 (en) * 2000-04-10 2002-08-20 Raven Biotechnologies, Inc. Human pancreatic epithelial progenitor cells and methods of isolation and use thereof
WO2002022163A1 (en) 2000-09-13 2002-03-21 Chugai Seiyaku Kabushiki Kaisha Remedies for ischemic diseases
BR0306902A (pt) * 2002-01-14 2006-04-11 Ford Henry Health System materiais de células estromais de medula óssea para uso na formação de vasos sanguìneos e produção de fatores angiogênicos e tróficos
CN100402654C (zh) 2003-02-19 2008-07-16 株式会社载体研究所 缺血疾病的治疗方法
SG146666A1 (en) * 2003-09-17 2008-10-30 Macropore Biosurgery Inc Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
US20060045872A1 (en) 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
JPWO2006134951A1 (ja) * 2005-06-13 2009-01-08 株式会社バイオマスター 脂肪由来幹細胞の長期培養増殖法
ATE419334T1 (de) * 2005-07-29 2009-01-15 Stiftung Caesar Verfahren zur isolierung von stammzellen aus ein kissenformiges gewebe der zähne

Also Published As

Publication number Publication date
KR20080103637A (ko) 2008-11-28
WO2008147057A1 (en) 2008-12-04
CN101711160B (zh) 2013-04-24
CN101711160A (zh) 2010-05-19
EP2162141A1 (en) 2010-03-17
US20100196329A1 (en) 2010-08-05
JP2010528107A (ja) 2010-08-19
JP5290281B2 (ja) 2013-09-18
EP2162141A4 (en) 2011-01-26
EP2162141B1 (en) 2013-09-11
ES2431816T3 (es) 2013-11-28

Similar Documents

Publication Publication Date Title
MX2009012666A (es) Composicion para el tratamiento de enfermedades isquemicas de las extremidades que se componen de celulas madre derivadas de tejido adiposo.
WO2011049414A3 (ko) 지방조직 유래 성체 줄기세포 이동을 유도하는 방법
WO2005000245A3 (en) Compositions and methods for increasing telomerase activity
WO2009061447A3 (en) Use of umbilical cord blood in the treatment of premature birth complications
MX2013002381A (es) Celulas precursoras cd27 1 derivadas de medula osea para reparacion cardiaca.
IL212958B (en) Placental stem cells for the treatment of diseases, syndromes or conditions of the lungs
WO2008013966A3 (en) Use of 8-quinolinol and its analogs to target cancer stem cells
TW200637488A (en) Compositions containing botanical extracts rich in phlorizin and methods for using such compositions in blood glucose modification and to affect aging
WO2006127007A3 (en) Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
WO2009151907A3 (en) Compositions and methods for using cells to treat heart tissue
WO2010007031A3 (en) Methods for improving cardiac differentiation of human embryonic stem cells
WO2007024441A3 (en) Compositions of cells enriched for combinations of various stem and progenitor cell populations, methods of use thereof and methods of private banking thereof
MX2009007247A (es) Metodo para el tratamiento de afecciones asociadas con actividad aumentada de 5-lipoxigenasa y/o leucotrienos.
MX2019004314A (es) Composición de apósito tópico para el tratamiento de tejido cutáneo dañado.
WO2007019107A3 (en) Adipose tissue stem cells, perivascular cells and pericytes
CN103110936A (zh) 一种促进皮肤组织快速生长修复的生物制剂
WO2014165723A3 (en) Enhanced osteogenic activity of daidzein analogs on human mesenchymal stem cells
EP2063902A4 (en) THERAPEUTIC CELL MEDICAMENT WITH STEM CELLS OF SKIN
WO2008134752A3 (en) Methods and compositions for the treatment of cancer
BRPI0914473A2 (pt) "célula-tronco de próstata e de câncer de próstata, métodos de isolamento de uma célula-tronco de próstata e de seleção de um paciente com câncer de próstata e métodos para inibir a proliferação de uma célula-tronco de próstata, para a prevenção de recidiva de câncer de próstata, para tratamento de câncer de próstata, para fornecimento de terapia adjuvante, para promover o crescimento ou reparação do tecido da próstata, para promover o crescimento da próstata, para fornecimento de próstata funcional e para selecionar um composto"
IL190289A0 (en) Method for obtaining human smooth muscular cells and uses thereof
WO2009046346A8 (en) Stem cell therapy for weight loss
WO2006091841A3 (en) Compositions and their uses directed to il-4r alpha
WO2008011473A3 (en) Compositions and their uses directed to hbxip
WO2010056988A9 (en) Methods of treating stroke using stem cell-like menstrual blood cells

Legal Events

Date Code Title Description
FG Grant or registration